Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2000

View Archived Issues

MedImmune moves three new products into the clinic in 1999

Wyeth-Ayerst makes EAAT-related milestone payment to Neurocrine Biosciences

Oculex updates intraocular drug delivery pipeline

Sporanox Injection now available for treatment of serious fungal infections

Atrix reports progress in Atrigel leuprolide formulations

Avonex MS trial stopped early, results positive

Amarillo Biosciences' oral interferon alfa granted orphan drug status for Behcet's disease

AEterna to commence phase III trial of AE-941 in second cancer indication

Teva signs definitive agreement to acquire Novopharm

Telithromycin featured in multiple presentations at ICMASKO 5

Berlex seeks FDA approval of long-acting intrauterine contraceptive

Memantine diminishes pain in diabetic neuropathy

InKine files patent for novel antiangiogenic protein

InterMune begins phase II trial of Actimmune in cryptococcal meningitis

Bexarotene now on the market in U.S.

COX-2 inhibitor now available for FAP indication

Cognetix, Elan team up to develop novel analgesic/drug delivery system

Novel foscarnet prodrugs show significantly enhanced activity against drug-resistant HIV

Novel analgesic compounds reported by Gruenenthal

Antitumor epothilone derivatives reported in patent literature by Schering AG

Draxis initiates phase III clinical trials with Fibrimage

New agents for imaging, treating angiogenic disorders under study at DuPont Pharmaceuticals

BMS prepares new tryptase inhibitors particularly useful for asthma

Newly patented hydrazine derivatives from Roche inhibit TNF-alpha release

RenaGel receives marketing approval in the E.U.

Medicure receives patent allowance for new antihypertensive drug

News from ICMASKO 5: Pliva describes new azalides

Oral valganciclovir is as effective as i.v. ganciclovir, with fewer complications

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...